Syringin reduces cellular senescence and pulmonary fibrosis in mice and cell models
Computational screening identified the natural compound, which interacts with CHK1 to blunt replication stress and fibrotic signaling.
Chinese journal of natural medicines · Wang Y et al. · Paper published 1 Oct 2026
In human lung datasets, cultured fibroblasts, and mice with bleomycin-induced lung injury, researchers investigated how targeting senescence could treat idiopathic pulmonary fibrosis. The team analyzed bulk and single-cell RNA sequencing data to map senescence programs, identifying senescent fibroblasts as key drivers expressing senescence-associated secretory phenotype factors. Using compound prioritization algorithms, they identified syringin, a plant-derived phenylpropanoid glycoside. In TGFβ1-stimulated fibroblasts and bleomycin-treated mice, syringin attenuated fibroblast activation, reduced senescence markers, and relieved pulmonary fibrosis. Mechanistically, syringin counteracted replication stress-associated signaling. Molecular assays and docking indicated that syringin interacts with CHK1, and knocking down CHK1 partially blocked syringin's effects on the ATR/CHK1-p53 pathway.
Why it matters
Idiopathic pulmonary fibrosis closely tracks chronological aging and involves senescent cell accumulation. Targeting senescence-associated replication stress pathways may offer a viable therapeutic approach for age-related fibrotic lung disorders.
Caveats
The in vivo therapeutic findings rely on a chemically induced mouse model, which does not fully capture chronic human disease. Clinical studies are necessary to evaluate the safety and efficacy of syringin in human patients.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis
Wang Y, Yin G, Niu M et al.
Chinese journal of natural medicines · 1 Oct 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.